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Abstract
Diabetic nephropathy (diabetic kidney disease) is defined as a rise in urinary albumin excretion rate,
often associated with an increase in blood pressure, and typically with concomitant retinopathy but
without evidence of other causes of renal disease. It is characterized first by albuminuria and then by a
progressive decline in glomerular filtration rate, eventually resulting in end-stage renal disease
(ESRD). Diabetic nephropathy occurs in approximately 30-35% of type 1 and type 2 patients and
tends to cluster in families. Diabetic kidney disease is associated with a very marked increase in
cardiovascular disease and, even from the earliest stages, with microalbuminuria. A diabetic milieu is
required for the diabetic glomerular lesion to develop, and the renin angiotensin aldosterone system
(RAAS) has been implicated in the development and progression of diabetic nephropathy. Most
patients with diabetes and renal impairment die from a cardiovascular disease event before they
progress to ESRD. From the studies described in this review, we think that clear evidence of RAAS
inhibition in the prevention of diabetic nephropathy is lacking and more studies are warranted.
Nevertheless, tight blood pressure control with inhibitor of RAAS and multifactorial intervention
(glycaemic, lipid control and so on) are warranted for secondary prevention and treatment of chronic
kidney disease in diabetes.
Introduction and context
Diabetic nephropathy (diabetic kidney disease) is
defined as a rise in urinary albumin excretion rate,
often associated with an increase in blood pressure, and
typically with concomitant retinopathy but without
evidence of other causes of renal disease [1,2]. It is
characterized first by albuminuria and then by a
progressive decline in glomerular filtration rate, even-
tually resulting in end-stage renal disease (ESRD). It is
usually accompanied by hypertension and, in the later
stages of diabetic kidney disease, by anaemia. Diabetic
nephropathy occurs in approximately 30-35% of type 1
and type 2 patients and tends to cluster in families.
Diabetic kidney disease is associated with a very marked
increase in cardiovascular disease and, even from the
earliest stages, with microalbuminuria [3].
A diabetic milieu is required for the diabetic glomerular
lesion to develop, and the renin angiotensin aldoster-
one system (RAAS) has been implicated in the devel-
opment and progression of diabetic nephropathy. The
all-cause mortality in patients with diabetic nephro-
pathy is nearly 20-40 times higher than that in patients
without nephropathy and is 2-5 times higher than with
other forms of chronic kidney disease [3]. Most patients
with diabetes and renal impairment die from a
cardiovascular disease event before they progress to
ESRD.
Diabetic nephropathy is the most common cause of
ESRD worldwide and represents about 30-40% of all
patients receiving renal replacement therapy in the
Western world [4]. Early intervention is therefore key to
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vascular complication.
Recent advances
Multifactorial treatment approaches (e.g., hypoglycae-
mic, antihypertensive, and cholesterol-reducing) are now
widely recommended in guidelines to be implemented
in the treatment of renal disease in diabetes at the earliest
stages, and inhibitors of RAAS appear particularly
effective in delaying progression toward end-stage renal
failure. What is not so clear, however, despite the
realization that ‘metabolically harmful’ drugs like
thiazide diuretics and beta blockers are associated in
middle-aged hypertensive patients with a higher inci-
dence of de novo diabetes, is whether targeted introduc-
tion of RAAS inhibitors can prevent the development of
diabetic nephropathy. In a recent study, Mauer and
colleagues [5] tested whether blockade of the RAAS
system (using either angiotensin-converting enzyme
[ACE] inhibitors or angiotensin receptor blockers
[ARBs]) before the onset of albuminuria in patients
with type 1 diabetes could slow progression of the early
histological lesions of diabetic nephropathy.
The findings on the prevention of diabetic nephropathy
were discouraging; the changes in the fraction of
glomerular volume occupied by mesangium did not
differ from those of the placebo, enalapril or losartan
groups, and worryingly, Mauer and colleagues observed
that albuminuria was more common in the losartan
group than in the placebo group, and more patients in
the losartan group progressed to microalbuminuria than
was the case in the enalapril or placebo groups [6]. The
interpretation of these data is difficult, but we can
speculate that a degree of RAAS activation is important
and might be ‘protective’ in the kidney. Excessive RAAS
inhibition in conditions in which it might not be
significantly activated (e.g., normotensive normoalbu-
minuric patients) could be detrimental. Often in experi-
mental and clinical research, we observe that a balanced
activation of any biological pathway is crucial and that
excessive inhibition or activation is to be avoided.
Similar results were observed in the EURODIAB
Controlled Trial of Lisinopril in Insulin-Dependent
Diabetes (EUCLID) study. In that study, the effect of
the ACE inhibitor lisinopril on the progression of renal
disease in normotensive type 1 diabetic patients with
normoalbuminuria or microalbuminuria was investi-
gated; no clear nephroprotective effect was observed in
type 1 diabetic patients with normoalbuminuria, but a
clear antiproteinuric effect of lisinopril was seen in
microalbuminuric patients [6]. Similarly, the Diabetic
Retinopathy Candesartan Trial (DIRECT) failed to
demonstrate, in a post hoc analysis, any effect of the
ARB candesartan on the development of microalbumi-
nuria in type 1 diabetic patients [7].
In summary, it appears that there is no evidence of a
benefit on structural/functional parameters from the
blockade of RAAS with an ACE inhibitor or an ARB
in normotensive patients with type 1 diabetes and
normoalbuminuria. So, at the moment, the blanket
prescription of an ACE inhibitor or an ARB to patients
with diabetes, but without any cardiovascular or renal
disease, cannot yet be recommended, and blood pressure
should be treated along the lines indicated by the Joint
British Societies guidelines (JBS-2) [8].
The observed changes in albuminuria are not always
associated with a commensurate alteration/decline in
renal function, especially in early diabetic nephropathy,
and we should be aware of a potential uncoupling of
albuminuria and renal function, especially in the early
phase of renal disease in diabetes [9].
If we focus on type 2 diabetes, specifically in the United
Kingdom Prospective Diabetes Study (UKPDS), better
control of blood pressure (achieved mean blood pressure
of 144/82 mm Hg) as compared with ordinary control
(mean blood pressure of 154/87 mm Hg) translated into
a 29% risk reduction of developing microalbuminuria
over the course of a 6-year period. Treatments with an
ACE inhibitor (captopril) and a beta blocker (atenolol)
were equally effective but the study was not powered to
detect between-drug differences [10]. Continued good
blood pressure control is critical because, unlike glycae-
mic control, there was no legacy effect in the UKPDS
follow-up on microvascular complications as blood
pressure control worsened [11,12].
The Bergamo Nephrologic Diabetes Complications
Trial (BENEDICT) found that the risk of developing
microalbuminuria was reduced by about 50% by
the use of the ACE inhibitor trandolapril but not
by verapamil for equivalent blood pressure reduction
in hypertensive patients with type 2 diabetes and
normoalbuminuria [13].
The Action in Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation (ADVANCE)
blood pressure trial showed that, in patients with type 2
diabetes, treatment with perindopril and indapamide
(a thiazide diuretic) reduced renal events (predomi-
nantly new-onset microalbuminuria) by nearly 21%
compared with conventional antihypertensive treatment.
Achieved blood pressure was lower in the perindopril/
indapamide group [14].
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Randomised Olmesartan and Diabetes Microalbumi-
nuria Prevention (ROADMAP) study, recently presented
at an American Society of Nephrology meeting [15]. In
that study, a significant effect of the angiotensin-receptor
blocker olmesartan medoxomil (against placebo) on the
development of microalbuminuria was observed in
normoalbuminuric mildly hypertensive patients with
type 2 diabetes on no treatment with inhibitors of the
RAAS. From this preliminary information, it appears that
the reduced incidence in new microalbuminuria
observed in the olmesartan group can be attributed
only partly to blood pressure control and that a
significant effect is to be attributed to the direct action
(presumably on renal vasculature) of olmesartan.
At variance with these studies, DIRECT failed to
demonstrate, in a post hoc analysis, any effect of the
ARB candesartan on the development of microalbumi-
nuria in type 2 diabetic patients (similarly to type 1
diabetic patients as noted above) with preserved renal
function (creatinine of less than 133 mmol/L) [7]. This
was despite lower blood pressure levels in the cande-
sartan-treated group.
Similarly, the Microalbuminuria, Cardiovascular, and
Renal Outcomes-Heart Outcomes Prevention Evaluation
(MICRO-HOPE) study [16], conducted in type 2 diabetic
patients, studied the effect of the ACE inhibitor ramipril
on myocardial infarction,stroke,or cardiovascular death.
Ramipril had a significant reduction on the primary
cardiovascular endpoint, but asignificant role of ramipril
on diabetic nephropathy was seen in microalbuminuric
patients only, whereas no clear effect was observed
between the intervention and placebo groups on the
development of new microalbuminuria in patients not
presenting this condition at baseline.
It would appear that a potential positive effect of RAAS
inhibition is seen mainly in significantly hypertensive
populations (UKPDS, BENEDICT, ADVANCE, and
ROADMAP) and less in studies conducted in more
normotensive and less ‘at risk’ normoalbuminuric
diabetic patients (EUCLID, MICRO-HOPE, DIRECT),
again possibly highlighting the importance of a balanced
RAAS activation/ inhibition.
Implications for clinical practice
From the studies described above, we think that clear
evidence of RAAS inhibition in the prevention of
diabetic nephropathy is lacking and more studies are
warranted. Nevertheless, tight blood pressure control
with inhibitor of RAAS and multifactorial intervention
(glycaemic, lipid control and so on) are warranted for
secondary prevention and treatment of chronic kidney
disease in diabetes.
Abbreviations
ACE, angiotensin-converting enzyme; ADVANCE, Action
in Diabetes and Vascular Disease: Preterax and Diami-
cron MR Controlled Evaluation; ARB, angiotensin
receptor blocker; BENEDICT, Bergamo Nephrologic
Diabetes Complications Trial; DIRECT, Diabetic Retino-
pathy Candesartan Trial; ESRD, end-stage renal disease;
EUCLID, EURODIAB Controlled Trial of Lisinopril in
Insulin-Dependent Diabetes; MICRO-HOPE, Microalbu-
minuria, Cardiovascular, and Renal Outcomes-Heart
Outcomes Prevention Evaluation; RAAS, renin angioten-
sin aldosterone system; ROADMAP, Randomised Olme-
sartan and Diabetes Microalbuminuria Prevention;
UKPDS, United Kingdom Prospective Diabetes Study.
Competing interests
LGdeclaresthathehasnocompetinginterestsonthetopic
covered. DG has received speaking and consultancy
honoraria from Merck (Darmstadt, Germany), sanofi-
aventis (Paris, France), Pfizer Inc. (New York, NY, USA)
and Bristol-Myers Squibb Company (Princeton, NJ, USA).
References
1. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H:
Microalbuminuria as a predictor of clinical nephropathy in
insulin-dependent diabetes mellitus. Lancet 1982, 1:1430-2.
2. Gnudi L, Thomas SM, Viberti G: Mechanical forces in diabetic
kidney disease: a trigger for impaired glucose metabolism.
J Am Soc Nephrol 2007, 18:2226-32.
3. Karalliedde J, Viberti G: Microalbuminuria and cardiovascular
risk. Am J Hypertens 2004, 17:986-93.
4. Ritz E: Nephropathy in type 2 diabetes. J Intern Med 1999,
245:111-26.
5. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T,
Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal
and retinal effects of enalapril and losartan in type 1 diabetes.
N Engl J Med 2009, 361:40-51.
Changes Clinical Practice
f1000 Factor 10.1 Exceptional
Evaluated by John Sedor 10 Jul 2009, Timothy Lyons 14 Jul 2009,
Enyu Imai 24 Jul 2009, Giuseppe Remuzzi 15 Sep 2009, Carl Erik
Mogensen 12 Oct 2009
6. Chaturvedi N; The EUCLID study group: Randomised placebo-
controlled trial of lisinopril in normotensive patients with
insulin-dependent diabetes and normoalbuminuria or micro-
albuminuria. Lancet 1997, 349:1787-92.
7. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T,
Porta M, Parving HH: Effect of candesartan on microalbumi-
nuria and albumin excretion rate in diabetes: three rando-
mized trials. Ann Intern Med 2009, 151:11-4.
8. British Cardiac Society; British Hypertension Society; Diabetes UK;
HEART UK; Primary Care Cardiovascular Society; Stroke Association:
JBS 2: Joint British Societies’ guidelines on prevention
of cardiovascular disease in clinical practice. Heart 2005,
91(Suppl 5):v1-52.
9. Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ:
Lowering of proteinuria in response to antihypertensive
therapy predicts improved renal function in late but not in
Page 3 of 4
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:18 http://f1000.com/reports/medicine/content/2/18early diabetic nephropathy: a pooled analysis. Am J Nephrol
2008, 28:614-27.
10. Bilous R: Microvascular disease: what does the UKPDS tell us
about diabetic nephropathy? Diabet Med 2008, 25(Suppl 2):25-9.
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year
follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med 2008, 359:1577-89.
f1000 Factor 6.0 Must Read
Evaluated by Wolfgang Schoels 29 Jun 2009
12. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term
follow-up after tight control of blood pressure in type 2
diabetes. N Engl J Med 2008, 359:1565-76.
f1000 Factor 4.8 Must Read
Evaluated by Robert Anderson 14 Oct 2008, Giuseppe Remuzzi
22 Oct 2008
13. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N,
Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A,
Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic
Diabetes Complications Trial (BENEDICT) Investigators: Preventing
microalbuminuria in type 2 diabetes. N Engl J Med 2004,
351:1941-51.
14. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J,
Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M,
Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS,
Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B: Effects of a
fixed combination of perindopril and indapamide on macro-
vascular and microvascular outcomes in patients with type 2
diabetes mellitus (the ADVANCE trial): a randomised
controlled trial. Lancet 2007, 370:829-40.
f1000 Factor 3.2 Recommended
Evaluated by Phyllis August 29 Nov 2007, Jerome Fleg 13 Dec 2007
15. Haller HG: Prevention of albuminuria and cardiovascular
morbidity with olmesartan: the ROADMAP trial. Paper
presented at American Society of Nephrology Renal Week 2009: 27
October - 1 November 2009; San Diego, CA, USA. Abstract 7026.
16. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators:
Effects of ramipril on cardiovascular and microvascular
outcomes in people with diabetes mellitus: results of the
HOPE study and MICRO-HOPE substudy. Lancet 2000,
355:253-9.
Page 4 of 4
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:18 http://f1000.com/reports/medicine/content/2/18